298 results about "Nitric oxide gas" patented technology

Methods for suppressing, killing, and inhibiting pathogenic cells, such as microorganisms associated with a respiratory infection within the respiratory tract of an animal are described. Methods include the step of exposing the pathogenic cells to an effective amount of nitric oxide, such as through inhalation of nitric oxide gas, in combination with traditional respiratory infection agents, such as antibiotics.

A system and a method topically applies nitric oxide to an infected area of tissue to treat a wound or lesion to prevent infection, reduce pathogen levels in the infected area and promote healing. The basic system includes a source of nitric oxide gas and a flushing envelope. The flushing envelope is applied to an animal to cover a wound and receives nitric oxide from the source via a flow control valve. One form of the system includes a vacuum unit fluidically connected to the flushing envelope, and one embodiment includes a gas absorber unit. The flushing envelope is adapted to surround the area of the infected tissue and form a substantially air-tight seal with the tissue surface when the flushing envelope is in place on the animal. The flow control valve controls the amount and concentration of nitric oxide gas that is delivered to the flushing envelope. A source of dilutant gas is fluidically connected to the flow control valve and a system control unit transmits and receives signals from various sensors and controlled elements in the system. NO and NO2 sensors are included in one form of the system.

Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.

Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site. After a first treatment period with high concentration of nitric oxide, a second treatment period at a lower concentration of nitric oxide preferably ranging from about 5-20 ppm may to provided to restore the balance of nitric oxide and induce collagen expression to aid in the closure of the wound.

The invention provides a method for preparing a nitric oxide-releasing medical device. The method includes contacting an amine-functionalized silane residue with a substrate, e.g., a metallic substrate, contacting the amine-functionalized silane residue with a cross-linking agent, contacting at least one nucleophilic residue with the cross-linked amine-functionalized silane residue, and contacting the nucleophilic residue with nitric oxide gas. The invention also provides a method of contacting the cross-linked amine-functionalized silane residue with at least one nitric oxide-releasing functional group. Furthermore, the invention provides a medical device for delivering nitric oxide in therapeutic a concentration, wherein the device comprises a substrate having nitric oxide bound thereto through diazeniumdiolated nucleophiles bonded to silane intermediates. The silane intermediates are bonded to the substrate and are amine-functionalized and cross-linked.

An exhaust gas post treatment system for nitrogen oxide and particle reduction of internal combustion engines operated with excess air. An oxidation catalytic converter is disposed in the exhaust gas stream of the engine for converting at least a portion of the nitric oxide in the exhaust gas into nitrogen dioxide. The first particle separator or filter is disposed in the exhaust gas stream downstream of the oxidation catalytic converter for converting carbon particles accumulated in the separator or filter into carbon monoxide, carbon dioxide, nitrogen and nitric oxide with the aid of nitrogen dioxide contained in the exhaust gas. A partial exhaust gas stream is branched off from the exhaust gas stream upstream of the first separator or filter. A metering device adds reduction agent to the partial exhaust gas stream in the form of ammonia or a material that releases ammonia downstream of the supply location due to hot exhaust gas. A second particle separator or filter is disposed in the partial exhaust gas stream downstream of the supply location. The partial exhaust gas stream returns to the exhaust gas stream downstream of both particle separators or filters. An SCR catalytic converter is disposed downstream of the return location for reducing nitrogen oxides in the exhaust gas to nitrogen and water vapor with the aid of ammonia or released ammonia by way of selective catalytic reduction.

The present invention is directed to a nitric gas dispenser for mammals on the run. The dispenser has a housing that contains a valve mechanism. The valve mechanism is interconnected between a nitric gas dispersal component that provides nitric gas at a desired pressure and a gas delivery system that provides the nitric gas at the desired pressure to the mammal. The valve mechanism controls the flow of the nitric gas between the nitric gas dispersal component and the gas delivery system. The dispenser also has a pressure sensor that is positioned along the gas delivery system and determines when the mammal is taking a breadth. If the pressure sensor determines the mammal is taking a breadth, the pressure sensor transmits a breadth signal to a microprocessor. The microprocessor then determines if the mammal is within a prescribed time frame for the mammal to be administered nitric gas. If the microprocessor determine the mammal is within the prescribed time frame, the microprocessor transmits an open signal to the valve mechanism to release a predetermined amount of nitric oxide gas to the mammal.

The administration of gaseous nitric oxide as a biocidal moiety is proffered as a de novo treatment in the control and eradication of biofilms. The present invention relates to the use or methods of application of exogenous nitric oxide gas (gNO) as a stand alone biocidal agent or in cohort with any or all adjunct vehicles in the control of biofilms generated by microbial organisms, i.e., bacteria, protozoa, amoeba, fungi etc. Further, the present invention introduces the concept of utilization and methods of application of gaseous nitric oxide in control and eradication of biofilm forming microorganisms. Noteworthy areas of application are offered as examples. They include, and are not limited to, air and/or water heating/cooling distribution systems in facilities such as hospitals and laboratories, surfaces of medical devices, household surfaces, dental plaque, dental and/or medical water treatment lines, industrial pipelines, water treatment and distribution facilities and fluids sterilization. Various specialized delivery apparatus will be designed to facilitate nitric oxide gas administration to each specific unique application.

A method and corresponding device are described for combating microbes and infections by delivering intermittent high doses of nitric oxide to a mammal for a period of time and which cycles between high and low concentration of nitric oxide gas. The high concentration of nitric oxide is preferably delivered intermittently for brief periods of time that are interspersed with periods of time with either no nitric oxide delivery or lower concentrations of nitric oxide. The method is advantageous because at higher concentration, nitric oxide gas overwhelms the defense mechanism of pathogens that use the mammalian body to replenish their thiol defense system. A lower dose or concentration of nitric oxide gas delivered in between the bursts of high concentration nitric oxide maintains nitrosative stress pressure on the pathogens and also reduces the risk of toxicity of nitric oxide gas.

Gas packages for the delivery of therapeutic gases, and in particular gaseous nitric oxide (gNO) are provided herein. The gas packages comprise one or more of a gas reservoir, interface layer, sealing layer, and holding container. The interface layer regulates discharge of the therapeutic gas from the gas reservoir to the external environment. The sealing layer and/or holding container prevent evolution of the gas until the sealing layer is compromised or the holding container is opened. The gas packages and methods for using them are useful for the treatment, alleviation, and prevention of various disease and non-disease, medical and non-medical, conditions in humans and animals.

A device for the topical delivery of nitric oxide gas to an infected area of skin includes a source of nitric oxide gas, a bathing unit, a flow control valve, and a vacuum unit. The bathing unit is adapted to surround the area of the infected skin and form a substantially air-tight seal with the skin surface. The bathing unit is also in fluidic communication with the source of nitric oxide. The flow control valve is position downstream of the source of nitric oxide and upstream of the bathing unit. The flow control valve controls the amount of nitric oxide gas that is delivered to the bathing unit. The vacuum unit is positioned downstream of the bathing unit and is used to withdraw gas from the bathing unit. Application of nitric oxide gas to the infected area of skin reduces levels of bacteria in the infected area and promotes the healing process.

Disclosed a nitric oxide supply system of respiratory failure rescue device belongs to the disease therapy apparatus, which avoids the high concentration NO gas cylinder, the high concentration dry gas cylinder and the nitrogen-oxygen mixed gas cylinder. The invention uses the air as raw material for attaining the NO at any time without the storage and via controlling the electric discharge condition, generates NO gas at most with least NO2 harmful gas to attain the low ratio of NO2/NO. While the concentration of NO ranges from 0-200 ppm in the pulse frequency of 1-90 Hz. The invention comprises an air pump connected in series to the gas passage, a clean-dry air generating device, a flow counter, a pulse generate and control circuit, a arc discharge reactor, a particle filter film, a NO2 catalytic reduction conversion apparatus, a cooler, a particle filter film, a selective absorber and a gas monitor.

A system and method for topically treating a wound or lesion of tissue to prevent infection includes applying nitric oxide gas to the wound or lesion. The basic system includes a source of nitric oxide gas and a flushing envelope. The flushing envelope is applied to a patient to cover a wound or lesion and receives nitric oxide from the source via a flow control valve. One form of the system also includes a vacuum unit fluidically connected to the flushing envelope, and one embodiment includes a gas absorber unit. The flushing envelope is adapted to surround the area of the infected tissue and form a substantially airtight seal with the tissue surface when the flushing envelope is in place on the patient. The flow control valve controls the amount of nitric oxide gas that is delivered to the flushing envelope. A source of dilutant gas is fluidically connected to the flow control valve and a system control unit transmits and receives signals from various sensors and controlled elements in the system. NO and NO2 sensors are included in one form of the system.

The present disclosure provides a device having a casing with a barrier surface and a contact surface and a composition in the casing having a nitric oxide precursor and an isolated enzyme or live cell expressing an endogenous enzyme, for converting the nitric oxide gas precursor to nitric oxide gas or having activity on a substrate that produces a catalyst that causes the conversion of the nitric oxide gas precursor to nitric oxide gas. The present disclosure also provides compositions, methods and uses for skin cosmesis.

A method of cleaning a film-forming apparatus to remove at least a part of a silicon-based material deposited on a constituent member of the film-forming apparatus after used to form thin films includes introducing a first-gas including fluorine gas and a second gas including nitrogen monoxide gas into the film-forming apparatus, and heating the constituent member. The constituent member includes quartz or silicon carbide, and the silicon-based material includes silicon nitride.

Tobaccos are cured in a manner so as to provide tobaccos having extremely low tobacco specific nitrosamine (TSNA) contents. Harvested Virginia tobacco is subjected to flue-curing so as to provide flue-cured tobacco. During the curing processing steps, contact of the tobacco with nitric oxide gases, such as those produced as combustion products of propane burning heating units, is avoided. Tobacco in curing barns is not subjected to direct-fire curing techniques, but rather, heat for tobacco curing can be provided by heat exchange or electrical heating methods.